secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-04-07T23:59:59+00:00
Accession:  0001104659-22-043424
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics appoints Wendy L. Dixon to board; Brad Bolzon resigns
--------------------------------------------------------------------------------

- Brad Bolzon resigned from the Board effective April 5, 2022; not due to any disagreement with the company.
- Wendy L. Dixon, Ph.D., appointed as Class III director effective April 6, 2022; deemed independent under Nasdaq rules.
- Dr. Dixon brings over 40 years biopharma experience, including former CMO of Bristol Myers Squibb and board seats at Alkermes, Incyte, Arvinas.
- She will receive standard non-employee director compensation and enter into an indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/0001104659-22-043424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/tm2211759d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-043424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer